Integrated Research Limited issues profit guidance. Here's what you need to know

Will the market send Integrated Research Limited (ASX:IRI) share price go higher or lower on Thursday?

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

What: At 5:25 pm on Wednesday evening, infrastructure and unified communications software developer Integrated Research Limited (ASX: IRI) released a market announcement to the ASX titled 'Profit Guidance'.

The statement noted that the company is anticipating both record revenue and record net profit after tax (NPAT) for the financial year ending 30 June 2016.

The guidance stated that revenue of between $81 million and $85 million is expected to be recorded, representing growth of between 15% and 20%. NPAT of between $15.3 million and $16 million is also expected, representing growth of between 7% and 12%.

So What: Integrated Research's share price touched a one-year low back in February after the group underwhelmed the market with an interim result which reported growth in revenue to $39 million but a decline in NPAT to $6.2 million (compared with the prior corresponding period).

The full year guidance implies that the company has achieved a much better profit performance in the second half.

Now What: It will be interesting to see how the market reacts to the 'Profit Guidance' on Thursday. Integrated Research enjoyed a currency tailwind in the first half, so analysts will be running the numbers to try and determine what effect currency had on the group's second half results.

At the mid-point of guidance, Integrated Research would appear to be trading on a price-to-earnings (PE) ratio of 23 times. While plenty of the company's peers including iSentia Group Ltd (ASX: ISD) and Altium Limited (ASX: ALU) are also trading on similarly high PEs, investors will ponder whether Integrated Research's constant currency growth rates justify its PE multiple.

Motley Fool contributor Tim McArthur has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »